CD24 blockade as a novel strategy for cancer treatment

Wang, Yawen; Yu, Haoran; Yu, Mengyuan; Liu, Hui; Zhang, Fangfang; Wang, Yuanyuan; Zhao, Simin; Xia, Qingjie

doi:10.1016/j.intimp.2023.110557

Cited by 4 publications

(4 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Understanding the interplay between CD24 and NKG2D opens new avenues for cancer immunotherapy. Strategies that target CD24 expression or function in cancer cells could enhance NKG2D-mediated immune responses, potentially overcoming immune evasion mechanisms and improving the efficacy of treatments designed to activate NK and T cells against cancer (15,167). This highlights the importance of exploring the roles of CD24 and NKG2D in cancer immunity and the potential for therapeutic interventions that modulate their activity.…”

Section: Cd24 and Nkg2d Receptormentioning

confidence: 99%

“…One of these mechanisms involves the upregulation of specific anti-phagocytic membrane proteins often referred to as "don't eat me" signals. These proteins include cluster of differentiation 47 (CD47) (13), cluster of differentiation 24 (CD24) (14,15), PD-L1 ( 16), the beta-2 microglobulin (b2M) subunit of the major histocompatibility class I complex (MHC-I) (17), stanniocalcin 1 (STC-1) (18), and GD2 (19). Phagocytosis is typically assisted by inherent "eat me" signals that serve as ligands for phagocytic receptors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

From mechanism to therapy: the journey of CD24 in cancer

Zhao,

Wu,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

CD24 is a glycosylphosphatidylinositol-anchored protein that is expressed in a wide range of tissues and cell types. It is involved in a variety of physiological and pathological processes, including cell adhesion, migration, differentiation, and apoptosis. Additionally, CD24 has been studied extensively in the context of cancer, where it has been found to play a role in tumor growth, invasion, and metastasis. In recent years, there has been growing interest in CD24 as a potential therapeutic target for cancer treatment. This review summarizes the current knowledge of CD24, including its structure, function, and its role in cancer. Finally, we provide insights into potential clinical application of CD24 and discuss possible approaches for the development of targeted cancer therapies.

show abstract

Section: Cd24 and Nkg2d Receptormentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

From mechanism to therapy: the journey of CD24 in cancer

Zhao,

Wu,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Cancer stemness refers to the self-renewal and propagation abilities of cancer stem cells (CSCs), which play a critical role in tumor aggressiveness, drug resistance, and metastasis [89]. CSCs can be identified by several markers, including CD44, CD24, CD133, LGR5, SOX2, AQP5, ESA, PAF1, and CXCR4, although none of these markers is highly specific [90][91][92][93][94]. As a central component of the TME, CAFs are believed to interact with CSCs and maintain a favorable tumor niche, mainly through paracrine signaling [95].…”

Section: Cafs Contribute To Cancer Stemnessmentioning

confidence: 99%

Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy

Guo,

2024

Cancer Metastasis Rev

View full text Add to dashboard Cite

Tumor microenvironment (TME) has been demonstrated to play a significant role in tumor initiation, progression, and metastasis. Cancer-associated fibroblasts (CAFs) are the major component of TME and exhibit heterogeneous properties in their communication with tumor cells. This heterogeneity of CAFs can be attributed to various origins, including quiescent fibroblasts, mesenchymal stem cells (MSCs), adipocytes, pericytes, endothelial cells, and mesothelial cells. Moreover, single-cell RNA sequencing has identified diverse phenotypes of CAFs, with myofibroblastic CAFs (myCAFs) and inflammatory CAFs (iCAFs) being the most acknowledged, alongside newly discovered subtypes like antigen-presenting CAFs (apCAFs). Due to these heterogeneities, CAFs exert multiple functions in tumorigenesis, cancer stemness, angiogenesis, immunosuppression, metabolism, and metastasis. As a result, targeted therapies aimed at the TME, particularly focusing on CAFs, are rapidly developing, fueling the promising future of advanced tumor-targeted therapy.

show abstract

“…Recent research has shown that CD24, which is overexpressed on tumor cells, interacts with the inhibitory receptor Siglec-10 on macrophages ( 6 ). This interaction promotes immune escape of tumor cells and creates a new immune checkpoint in the form of a “don’t eat me” signal ( 7 , 8 ). Therefore, CD24 has become a potential therapeutic target for cancer treatments, including antibody drugs, gene therapy, chimeric antigen receptor (CAR) T cell therapy, and more ( 9 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

Checkpoint CD24 function on tumor and immunotherapy

Huang,

Zhang,

Wei

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

CD24 is a protein found on the surface of cells that plays a crucial role in the proliferation, invasion, and spread of cancer cells. It adheres to cell membranes through glycosylphosphatidylinositol (GPI) and is associated with the prognosis and survival rate of cancer patients. CD24 interacts with the inhibitory receptor Siglec-10 that is present on immune cells like natural killer cells and macrophages, leading to the inhibition of natural killer cell cytotoxicity and macrophage-mediated phagocytosis. This interaction helps tumor cells escape immune detection and attack. Although the use of CD24 as a immune checkpoint receptor target for cancer immunotherapy is still in its early stages, clinical trials have shown promising results. Monoclonal antibodies targeting CD24 have been found to be well-tolerated and safe. Other preclinical studies are exploring the use of chimeric antigen receptor (CAR) T cells, antibody-drug conjugates, and gene therapy to target CD24 and enhance the immune response against tumors. In summary, this review focuses on the role of CD24 in the immune system and provides evidence for CD24 as a promising immune checkpoint for cancer immunotherapy.

show abstract

CD24 blockade as a novel strategy for cancer treatment

Cited by 4 publications

References 120 publications

From mechanism to therapy: the journey of CD24 in cancer

From mechanism to therapy: the journey of CD24 in cancer

Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy

Checkpoint CD24 function on tumor and immunotherapy

Contact Info

Product

Resources

About